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tamponade,	 presentation	 to	 hospitals	 with	 high	 Balloon	 tamponade	 utilization	
	increases	their	odds	of	dying	from	acute	variceal	haemorrhage.
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tic	 antibiotics.5	Given	 the	 availability	 of	 these	 therapies	which	now	
constitute	the	standard	of	care,	BT	is	currently	reserved	for	patients	
too	 unstable	 for	 endoscopy	 or	 for	 whom	 endoscopic	 therapy	 has	
failed	or	is	technically	impossible.	In	this	context,	BT	utilization	is	an	
important	sentinel	event,	one	that	reflects	both	a	high	risk	of	mortality	







the	 patient	 of	 an	 endoscopist	 uncomfortable	with	 band-	ligation.	 In	
these	cases,	BT	use	speaks	to	problems	in	the	delivery	of	AVH	care.	
We	 recently	 showed	 that	 14%	 of	 all	 patients	with	AVH	 receive	 no	
endoscopic	 therapy,	 9%	 do	 not	 receive	vasoactive	medications	 and	
37%	do	not	receive	prophlylactic	antibiotics.4	We	hypothesized	that	
if	 a	 patient	 received	BT,	many	 others	would	 have	 been	 exposed	 to	
similar	processes	of	care	and	thus	higher	BT	utilization	at	the	hospital-	











data	are	useful	 in	determining	 the	 clinical	 associations	with	BT	and	
the	impact	of	BT	utilization	on	in-	hospital	mortality.	However,	the	NIS	
lacks	 the	 necessary	 data	 to	 link	BT	 use	 to	 established	 quality	met-





to	 determine	 the	 in-	hospital	 mortality	 associated	 with	 any	 given	
hospital’s	 ratio	of	BT	utilization	 (ICD-	9	CM	96.06)	to	the	volume	of	
patients	with	 a	 primary	 diagnosis	 of	 AVH	 (ICD-	9	 456.0	 or	 456.20)	
or	a	secondary	diagnosis	of	AVH	with	a	primary	diagnosis	of	cirrho-
sis	 (ICD-	9	 571.2	 571.5,	 571.6)	 or	 its	 complications	 including	 portal	
	hypertension	 (ICD-	9	 572.3),	 hepatic	 encephalopathy	 (HE;	 ICD-	9	
572.2),	 ascites	 (ICD-	9	 789.59)	 or	 hepatorenal	 syndrome	 (ICD-	9	
572.4).	The	analysis	was	restricted	to	hospitals	that	care	for	more	than	
10	patients	with	AVH	per	year.
We	 first	 compared	patient-	and	hospital-	level	 factors	associated	
with	BT	use.	Patient-	level	 included	demographics	 (gender,	race,	age,	
socioeconomic	 status),	 insurance	 payor,	 aetiology	 of	 liver	 disease	
	(alcohol,	viral),	liver	specific	comorbidities	(ascites,	HE,	hepatocellular	
carcinoma—HCC)	and	Charlson	score.6	Hospital-	level	factors	included	
size,	 transfer-	rate	and	 teaching	 status.	We	also	documented	 receipt	

















We	 also	 analysed	 a	 single-	centre	 cohort	 drawn	 from	 Beth	 Israel	
Deaconess	Medical	Center,	an	academic	tertiary	care	and	liver	trans-




•	 Optimal	 management	 includes	 timely	 endoscopy	 with	
band	ligation	and	vasoactive	medications
•	 Balloon	tamponade	 (BT)	 is	 reserved	for	bleeding	refrac-
tory	to	endoscopic	and	medical	management
•	 Balloon	 tamponade	may	be	associated	with	gaps	 in	 the	
quality	of	bleeding	management
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associated	 with	 the	 outcomes	 of	 oesophageal	 AVH	 from	 January	
2009	through	October	2015.	The	data	were	collected	prospectively	
from	 February	 2015	 forward	 and	 retrospectively	 otherwise.	 The	
Institutional	Review	Board	of	Beth	Israel	Deaconess	Medical	Center	
approval	with	a	waiver	of	informed	consent.	Patients	were	identified	
by	 electronically	 searching	 administrative	 data	 for	 inpatient	 endos-





cluded	 to	 simplify	 the	 interpretation	 of	 the	 data.	Demographic	 and	
clinical	details	were	collected	as	detailed	in	Table	1.
In	 this	 centre,	 all	 gastrointestinal	 haemorrhage	was	managed	by	
gastroenterology	 fellows	 in	 concert	 with	 specialized	 hepatologists	
if	 cirrhosis	was	established	or	 suspected	and	general	 academic	gas-
troenterologists	 otherwise—all	 of	 whom	 were	 familiar	 with	 AVH	
treatment	 protocols.	 Patients	 with	 AVH	were	 triaged	 to	 the	 inten-
sive	 care	 unit	 unless	 haemodynamically	 stable	 without	 transfusion	

















dure	model	 for	end-	stage	 liver	disease	 (MELD),	cirrhotic	decompen-










Wilcoxon	 Rank-	Sums	 test	 for	 pairwise	 comparisons	 of	 categorical	
variables,	 parametric,	 and	 non-	parametric	 continuous	 variables	 re-
spectively.	 A	 stepwise	 backward	 logistic	 regression	 procedure	 was	
performed	to	determine	the	adjusted	effect	on	BT	utilization	on	any	
variable	 found	 to	 be	 significant	 (two-	tailed	 P	<	.05)	 in	 the	 pairwise	
comparisons	(see	Table	1).	Since	BT	use	was	rare,	analyses	were	per-









portions	 were	 performed	 using	 t-	tests	 taking	 into	 account	 survey	
design	 (significance	 threshold	P	<	.05).	Multivariable	 logistic	 regres-
sion	was	performed	to	adjust	for	the	impact	of	BT	use:AVH	ratio	on	
in-	hospital	mortality	by	taking	into	account	patient	factors	(age,	sex,	
income,	 race,	 insurer,	 Charlson	 comorbidity	 index	 and	 liver	 disease	






Overall,	 we	 included	 140	521	 admissions	 for	 AVH	 in	 our	 study.	
Table	1	delineates	the	differences	between	patients	who	did	and	did	





BT	utilization	 to	AVH	volume.	Most	patients	were	cared	 for	 in	hos-
pitals	without	 reported	BT	use.	Among	hospitals	with	BT	utilization,	





utilization	 was	 examined	 in	 Table	3.	 As	 expected,	 cirrhotic	 comor-
bidities	were	associated	with	increased	risk	of	mortality	as	was	TIPS	






to	hospitals	with	highest	 tertile	of	BT	utilization	compared	 to	 those	
without	BT	use	(odds	ratio	1.20	95%	CI	(1.10-	1.32).	Adjusting	for	year	
of	service	did	not	alter	the	results.
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TABLE  1 Population	characteristics
Single center cohort
BT use n = 14 No BT use N = 125 P value
Age	(mean	±	SD) 61.4	(9.7) 58.0	(11.4) .28
Male	(%) 85.7 66.4 .22
English-	speaking	(%) 64.3 90.4 .02
Transplant	listed	(%) 8.0 14.3 .35
Active	alcohol	use	(%) 50.4 21.4 .04
Etiology	(%)




Ascites 71.4 52.0 .26
HE 39.2 35.7 1.00
HCC 35.7 8.8 .01
Admission	MELD	(median,	IQR) 26.3	(13.3-	37.3) 15.5	(11.4-	22.9) .002
Admit	hemoglobin 9.8	(1.8) 9.6	(1.7) .41
Active	bleeding	at	endoscopy 64.3 27.5 .01
Antibiotics	prior	to	endoscopy 95.2 100 1.00
Octreotide	prior	to	endoscopy 94.4 100 1.00
Endoscopy	within	12	h 71.4 88.8 .09
Band	ligation 67.4 95.2 .0002
Nationwide cohort
BT use N = 773 No BT use N = 139 747 P value
Age	(mean	±	SD) 52.60	(10.5) 54.57	(12.4) .02
Male	(%) 84.0 69.9 <.01
Race/Ethnicity	(%)








Alcoholic	liver	disease 72.6 57.6 <.01
Ascites 20.53 20.25 .9
HE 25.13 17.66 .03
HCC 5.62 3.23 .2
Charlson	score	(median,	IQR) 3	(3-	4) 3	(3-	4) .54
Payer	(%)




Teaching 64.6 57.3 .05
Small/Medium 22.5 24.7
Large 77.5 75.3
Endoscopy	during	hospitalization 85.3 84.6 .8
TIPS	placement 30.8 5.3 <.01
BT,	balloon	tamponade;	HE,	Hepatic	encephalopathy;	HCC,	Hepatocellular	carcinoma;	IQR,	interquartile	range;	MELD,	model	for	endstage	liver	disease;	
NASH,	nonalcoholic	steatohepatitis;	TIPS,	transjugular	intrahepatic	portosystemic	shunt.
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3.2 | Single- centre cohort
We	analysed	a	single-	centre	cohort	to	assess	the	reasons	for	BT	uti-







were	 numerically	 but	 not	 significantly	 less	 likely	 to	 receive	 timely	
endoscopy,	 octreotide	 and	 antibiotics,	 they	 were	 significantly	 less	
likely	 to	have	 received	band	 ligation.	 In	a	 logistic	 regression,	MELD	
and	 band-	ligation	 were	 significantly	 associated	 with	 BT	 utilization.	
Adjusting	to	MELD,	failure	to	band	was	associated	with	an	odds	ratio	





the	 14	 patients	 needing	 BT,	 the	 endoscopic	 therapy	 provided	 was	
as	 follows:	eight	 failed	attempts	at	banding	on	non-	bleeding	varices	
at	 the	 time	 of	 endoscopy	 (slipped	 band	 placement	 with	 recurrent	
haemorrhage),	five	no	treatment,	one	sodium	morrhuate	injection	and	










Balloon	 tamponade	 is	 a	 temporizing	 procedure	 used	 to	 “bridge”	
	patients	 from	 uncontrolled	 variceal	 haemorrhage	 to	 definitive	
therapy,	either	a	second	endoscopy	or	TIPS.	Given	the	limited	con-
temporary	data	available	on	BT	use,	the	authors	of	the	Baveno	VI	
consensus	 have	 recommended	 additional	 research	 on	 this	 topic.5 
In	this	study	of	nationally	representative	cohort	complemented	by	
granular	data	from	a	single	tertiary	care	centre,	we	show	that	while	
BT	utilization	 reflects	 both	 severity	 of	 liver	 disease	 and	bleeding,	
BT	use	 itself	may	 identify	 opportunities	 to	 improve	hospital-	level	
TABLE  2 Nationwide	cohort	characteristics	by	hospital-	level	bt	utilization
Nationwide cohort characteristics by hospital- level bt utilization





(%) Top tertile (%)




123	467 8735 5099 3220 –
In	hospital	death 8.1 10.9 11.8 14.0 .12
Other	disposition
Home	discharge 78.8 78.3 75.6 69.8 <.0001
SNF 7.1 6.9 6.6 8.1
Transfer 3.4 1.7 3.8 5.8
Other 2.6 2.2 2.2 2.3
Payer
Medicare 27.9 25.5 26.2 25.6 .002
Medicaid 22.9 23.9 30.8 26.2
Private 27.7 27.9 23.3 25.6
Self-	pay 13.1 12.1 12.0 17.1
Other 8.5 10.6 7.7 5.4
Hospital	type
Teaching 55.2 79.6 73.4 52.1 .001
Small/Medium 25.8 10.3 17.2 34.5 <.0001
Large 74.2 89.7 82.8 65.5
Interventions
Endoscopy 84.6 84.5 85.4 86.0 .56
TIPS 5.1 8.4 7.6 6.4 .21
BT,	balloon	tamponade;	SNF,	skilled	nursing	facility;	TIPS,	transjugular	intrahepatic	portosystemic	shunt.
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processes	of	care	for	patients	with	presenting	with	AVH	to	centres	
with	 high	AVH	 volume.	 Although	 it	 is	 a	 rare	 event	 that	 affects	 a	






ticularly	 active	 alcohol	 use	 and	 severity	 of	 underlying	 liver	 disease.	
Increased	 attention	 to	 prophylactic	 strategies	 for	 high-	risk	 patients	
is	warranted.	For	example	titration	of	prophylactic	beta	blockade	to	










to	use	vasoactive	medications.	 It	may	also	 indicate	a	 lack	of	opera-
tor	experience	with	active	haemorrhage	or	comfort	with	alternative	




lization	 is	 independently	 associated	with	poor	outcomes.	This	novel	









in	 hospitals	 performing	 ≥20	TIPS	 per	 year.13	Variance	 in	 procedure	












prior	 quality	 improvement	 intervention,	 however,	 has	 aimed	 to	 im-
prove	the	rate	or	effectiveness	of	band	ligation.	It	is	conceivable	that	
efforts	 to	 increase	 the	 utilization	 of	 pre-	endoscopy	 erythromycin17 
could	improve	visualization	and	increase	the	success	of	band-	ligation,	














cannot	be	 fully	 explained.	 For	 example	 as	many	 as	15%	of	patients	
with	AVH	did	not	receive	an	endoscopy	which	itself	reduced	mortality.	














Adjusted risk factors for in- hospital mortality
Odds ratio 95% Confidence interval
Patient	factors
Alcoholic	liver	disease 1.36 1.21 1.52
Ascites 1.24 1.10 1.39
Hepatic	encephalopathy 2.91 2.61 3.25
Hepatocellular	carcinoma 1.91 1.50 2.44
Utilization	of	bleeding	interventions
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(<10	AVH/y)	for	the	national	cohort,	these	data	are	not	explicitly	gen-
eralizable	 to	such	settings.	Third,	 these	data	cannot	account	 for	 the	
specific	contribution	of	gastric	varices	as	we	excluded	these	patients	
from	 the	 single-	centre	 cohort	 and	 the	 data	 from	 the	 national	 inpa-
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